Regeneron Partners with TriNetX in $200 Million Deal to Access 300 Million Patient Health Records for Drug Discovery
核心洞察
Regeneron has entered a strategic collaboration with TriNetX (搜索) to gain exclusive access to de-identified electronic health records from approximately 300 million patients worldwide.
The partnership will enable Regeneron to connect its genomic and proteomic data from the Regeneron Genetics Center (搜索) with TriNetX (搜索)'s global health data network to accelerate drug discovery.
Regeneron will invest up to $200 million in TriNetX (搜索) as part of the collaboration to expand its world-leading genomic database and develop AI-powered digital health solutions.
Regeneron Pharmaceuticals has announced a strategic collaboration with TriNetX (搜索) to access de-identified electronic health records from approximately 300 million patients globally, marking one of the largest health data partnerships in the pharmaceutical industry. The collaboration includes Regeneron's investment of up to $200 million in TriNetX and provides exclusive opportunities to integrate genomic and proteomic data with real-world health information.
Expanding Genomic Database Capabilities
Under the collaboration, TriNetX (搜索) will provide Regeneron with secure, licensed access to de-identified health data from approximately 300 million individuals, including 170 million in the United States. The data is sourced directly from TriNetX's global network of over 11,000 healthcare provider locations. Using privacy-preserving methods, Regeneron will have the capability to match portions of TriNetX's anonymized data to genomic and proteomic data generated by the Regeneron Genetics Center (搜索) (RGC).
"This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world's largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers," said Dr. Aris Baras, Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Medicines.
Leveraging AI for Drug Discovery
The RGC has developed high-throughput and cost-efficient DNA sequencing and proteomics approaches to build what the company describes as the world's largest database of EHR-linked sequencing and proteomics data. The center currently maintains a database of more than 3 million sequenced exomes with de-identified health information, developed through collaborations with over 150 life sciences and healthcare partners worldwide.
The collaboration with TriNetX (搜索) will enable expansion of this dataset to drive drug discovery and development while empowering artificial intelligence training algorithms to deliver digital health solutions. The RGC uses innovative technologies, including machine learning, to sequence exomes, align with health information and perform large-scale analyses to identify meaningful associations between genes and diseases.
Strategic Investment and Partnership
"Our RGC strategic investments catalyze innovation, driving advancements in cutting-edge technologies that accelerate drug discovery and development, as well as help us develop innovative digital health solutions," said Andrew Deubler, Senior Vice President, RGC Chief Business and Administrative Officer. "This deal represents the latest and one of our most significant collaborations."
Jeff Margolis, TriNetX (搜索) Executive Chairman, expressed enthusiasm about the partnership: "We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center (搜索) team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data."
Privacy and Compliance Framework
All data matching will be conducted in accordance with applicable data privacy laws, including HIPAA and GDPR. TriNetX (搜索)'s platform provides access to research-ready data across its extensive federated global network of academic medical centers and other leading healthcare research sites.
The collaboration represents a significant expansion of Regeneron's data capabilities as the company continues to develop treatments across multiple therapeutic areas, including eye diseases (搜索), allergic and inflammatory diseases (搜索), cancer (搜索), cardiovascular and metabolic diseases (搜索), neurological diseases (搜索), hematologic conditions (搜索), infectious diseases (搜索), and rare diseases (搜索).